Pharmaceutisch Weekblad

, Volume 2, Issue 1, pp 600–603 | Cite as

Het pneumokokkenvaccin, een entstof in ontwikkeling

  • H. C. Zanen


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ammann, A. J., e.a. (1977)New Engl. J. Med. 297, 897.Google Scholar
  2. Austrian, R. (1977)J. Infect. Diseases 136, Suppl. 538.Google Scholar
  3. Aery, O. T., C. M. Macleod enM. McCarty (1944)J. Exptl. Med. 79, 137.Google Scholar
  4. Cadman, E., e.a. (1978)New Eng. J. Med. 299, 1317.Google Scholar
  5. Giffith, F. (1928)J Hyg. (Lond.) 27, 113.Google Scholar
  6. Lund, E. (1971) In:Bayer-Symposium III,Finland, M.,W. Marget enK. Bartmann (Eds.) 49.Google Scholar
  7. Mäkelä, H. (1979)Efficacy of the 14-valent pneumococcal polysaccharide vaccine in preventing recurrencies of otitis media in infants and children. (WHO international conference on immunity and immunization in cerebrospinal meningitis.)Google Scholar
  8. Robbins, J. B. (1979)J. Infect. 1, Suppl. 2, 61.Google Scholar
  9. Wright, E. A., e.a. 1914)Lancet 1, 87.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1980

Authors and Affiliations

  • H. C. Zanen
    • 1
  1. 1.Bacterioloog te AmsterdamNetherlands

Personalised recommendations